PHARMACOKINETICS OF TETROXOPRIM-SULFADIAZINE IN PATIENTS WITH IMPAIRED RENAL-FUNCTION

被引:9
作者
REUTTER, FW [1 ]
VERGIN, H [1 ]
SIEBER, R [1 ]
FERBER, H [1 ]
机构
[1] HEUMANN RES DEPT,D-8500 NURNBERG,FED REP GER
关键词
D O I
10.1093/jac/5.Supplement_B.149
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
After the combined oral administration of tetroxoprim and sulphadiazine in 16 patients with normal or impaired renal function, a linear relationship was found between the elimination rate constant (ke) and the endogenous creatinine clearance (Clcr). The mean elimination half-life (t1/2) for tetroxoprim in patients with healthy kidneys was 6 7 h and in anuric patients 13 8 h. In the case of sulphadiazine the values were t1/2 = 10 4 h (healthy kidneys) and t1/2 = 25 7 h (anuria). Both drugs were influenced in the same way and in parallel with the functional condition of the kidneys. For long term administration in anuric patients a dosage interval of τ=24h is required. The relative distribution volumes Vf for both substances are independent of the degree of renal insufficiency. The mean Vf values are calculated as 0 77 ±0 11 1/kg for tetroxoprim, and 036 ± 0 07 1/kg for sulphadiazine. Fiir Tetroxoprim und Sulfadiazin werden nach gemeinsamer oraler Gabe lineare Beziehungen zwischen den Eliminationsgeschwindkeitskonstanten ke und der endogenen Creatininclearance (Clcr) bei 16 Patienten mit normaler bzw. geschadigter Nierenfunktion gefunden. Die mittleren Eliminationshalbwerts- zeiten betragen fiir Tetroxoprim bei nierengesunden Patienten t1/2 = 6 7 h und bei Anurikern t1/2 = 13 8 h. Im Falle von Sulfadiazin ergeben sich Werte von t1/2= 10'4 h (Nierengesunde) und t1/2, = 25 7 h (Anuriker). Die beiden Wirkstoffe werden demnach gleichsinnig urid parallel vom Funktionszustand der Nieren beeinflufit. Bei Langzeitgabe ist bei anurischen Patienten ein Dosierungsintervall von τ = 24 h zu fordem. Die relativen Verteilungsvolumina Vf zeigen bei beiden Wirksub- stanzen keine Abhangigkeit vom Schweregrad einer Niereninsuffizienz. Die mittleren Vf-Werte errechnen sich fiir Tetroxoprim zu 0 77 ± 0 11 1/kg und für Sulfadiazin zu 0 36 ± 0 07 1/kg. © 1979 Oxford University Press.
引用
收藏
页码:149 / 158
页数:10
相关论文
共 10 条
[1]  
DETTLI L, 1970, POSTGRAD MED J, V46, P32
[2]  
DETTLI L, 1971, ACTA PHARMACOL TOX, V29, P211
[3]   SHORT-TERM STUDY OF TETROXOPRIM-SULFADIAZINE IN THE TREATMENT OF ACUTE BRONCHITIS AND URINARY-TRACT INFECTIONS [J].
FERBER, H ;
AHRENS, KH ;
HAASE, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1979, 5 :231-235
[4]   BIOTRANSFORMATION OF TETROXOPRIM IN MAN [J].
KORN, A ;
FERBER, H ;
HITZENBERGER, G ;
VERGIN, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1979, 5 :139-147
[5]   ELIMINATION KINETICS OF SULFADIAZINE IN PATIENTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION [J].
OHNHAUS, EE ;
SPRING, P .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1975, 3 (03) :171-179
[6]   TREATMENT OF URINARY INFECTIONS WITH TETROXOPRIM-SULFADIAZINE [J].
PUST, R ;
FERBER, H ;
WEIDNER, W ;
ROTHAUGE, CF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1979, 5 :171-177
[7]  
REEVES DS, 1979, J ANTIMICROBIAL C SB, V5, P181
[8]   PHARMACOKINETICS OF TETROXOPRIM AND SULFADIAZINE IN VARIOUS SPECIES [J].
VERGIN, H ;
FRITSCHI, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1979, 5 :103-118
[9]  
VERGIN H, UNPUBLISHED
[10]  
WAGNER J, 1971, BIOPHARMACEUTICS REL, pJ11